308 related articles for article (PubMed ID: 15565413)
1. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
Yamaguchi M; Matsumoto T; Tate G; Higuchi T
J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
[No Abstract] [Full Text] [Related]
2. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
Zheng S; Jia J; Pan YL; Tao DY; Lu HS
Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
[No Abstract] [Full Text] [Related]
3. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
[TBL] [Abstract][Full Text] [Related]
4. Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11.
Kubota K; Katayama A; Takeshita Y; Nozaki K; Ueda T; Imamura K; Hiki N; Nomura S; Kaminishi M; Mafune K
Dig Dis Sci; 2007 Jul; 52(7):1725-9. PubMed ID: 17546507
[No Abstract] [Full Text] [Related]
5. [KIT mutation analysis in pathological diagnosis and target-therapy of gastrointestinal stromal tumors: an update].
Chen LR
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):440-3. PubMed ID: 17845754
[No Abstract] [Full Text] [Related]
6. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.
Wardelmann E; Thomas N; Merkelbach-Bruse S; Pauls K; Speidel N; Büttner R; Bihl H; Leutner CC; Heinicke T; Hohenberger P
Lancet Oncol; 2005 Apr; 6(4):249-51. PubMed ID: 15811621
[No Abstract] [Full Text] [Related]
7. [Clinical and molecular characterization of gastrointestinal stromal tumors (GIST)].
Mac K; Wójcik M
Postepy Hig Med Dosw (Online); 2007 Jun; 62():272-81. PubMed ID: 18542042
[TBL] [Abstract][Full Text] [Related]
8. Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation.
Graham J; Debiec-Rychter M; Corless CL; Reid R; Davidson R; White JD
Arch Pathol Lab Med; 2007 Sep; 131(9):1393-6. PubMed ID: 17824795
[TBL] [Abstract][Full Text] [Related]
9. [Consensus on the medical treatment of gastrointestinal stromal tumors].
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
[No Abstract] [Full Text] [Related]
10. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
[TBL] [Abstract][Full Text] [Related]
11. GIST under imatinib therapy.
Sciot R; Debiec-Rychter M
Semin Diagn Pathol; 2006 May; 23(2):84-90. PubMed ID: 17193821
[TBL] [Abstract][Full Text] [Related]
12. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769
[TBL] [Abstract][Full Text] [Related]
13. Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment.
Yeh CN; Chen TW; Liu FY; Jan YY; Chen MF
Langenbecks Arch Surg; 2006 Nov; 391(6):615-21. PubMed ID: 17024483
[TBL] [Abstract][Full Text] [Related]
14. New strategies for treating GIST when imatinib fails.
Boyar MS; Taub RN
Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
[TBL] [Abstract][Full Text] [Related]
15. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
16. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
[No Abstract] [Full Text] [Related]
17. Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment.
Koyama T; Nimura H; Kobayashi K; Marushima H; Odaira H; Kashimura H; Mitsumori N; Yanaga K
Gastric Cancer; 2006; 9(3):235-9. PubMed ID: 16952044
[TBL] [Abstract][Full Text] [Related]
18. Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case.
Utsunomiya T; Okamoto M; Yano S; Kameyama T; Matsuyama A; Kuma S; Yamamoto M; Fujiwara M; Ishida T
Surg Today; 2008; 38(1):65-7. PubMed ID: 18085368
[TBL] [Abstract][Full Text] [Related]
19. [Chinese consensus in diagnosis and treatment of gastrointestinal stromal tumor].
Chinese Diagnosis and Treatment Experts Group for Gastrointestinal Stromal Tumors
Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):697-702. PubMed ID: 20078976
[No Abstract] [Full Text] [Related]
20. C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.
Gao J; Dang Y; Sun N; Li J; Shen L
Med Oncol; 2012 Dec; 29(5):3039-45. PubMed ID: 22815156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
